Perrigo Company PLC banner

Perrigo Company PLC
NYSE:PRGO

Watchlist Manager
Perrigo Company PLC Logo
Perrigo Company PLC
NYSE:PRGO
Watchlist
Price: 12.025 USD -0.12%
Market Cap: $1.7B

EV/EBITDA

7.3
Current
34%
Cheaper
vs 3-y average of 11

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
7.3
=
Enterprise Value
$4.5B
/
EBITDA
$650.3m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
7.3
=
Enterprise Value
$4.5B
/
EBITDA
$650.3m

Valuation Scenarios

Perrigo Company PLC is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (11), the stock would be worth $18.22 (52% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+52%
Average Upside
50%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 7.3 $12.03
0%
3-Year Average 11 $18.22
+52%
5-Year Average 11 $18.28
+52%
Industry Average 11 $18.26
+52%
Country Average 10.6 $17.5
+46%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$4.5B
/
Jan 2026
$650.3m
=
7.3
Current
$4.5B
/
Dec 2026
$627.5m
=
7.2
Forward
$4.5B
/
Dec 2027
$692.2m
=
6.5
Forward
$4.5B
/
Dec 2028
$732.1m
=
6.2
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
IE
Perrigo Company PLC
NYSE:PRGO
1.7B USD 7.3 -1.2
US
Eli Lilly and Co
NYSE:LLY
869.1B USD 27.7 40.9
US
Johnson & Johnson
NYSE:JNJ
555.5B USD 16.5 25.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.7 19.8
UK
AstraZeneca PLC
LSE:AZN
231.9B GBP 16.2 29.2
CH
Novartis AG
SIX:NOVN
226.8B CHF 12.3 19.9
US
Merck & Co Inc
NYSE:MRK
289.8B USD 9.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8 10.9
US
Pfizer Inc
NYSE:PFE
156.5B USD 7.7 20
US
Bristol-Myers Squibb Co
NYSE:BMY
119B USD 7.1 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Perrigo Company PLC
NYSE:PRGO
Average EV/EBITDA: 46.4
7.3
4%
1.8
US
Eli Lilly and Co
NYSE:LLY
27.7
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
16.5
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.7
6%
2
UK
AstraZeneca PLC
LSE:AZN
16.2
12%
1.3
CH
Novartis AG
SIX:NOVN
12.3
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.5
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.7
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
P/E Multiple
Earnings Growth PEG
IE
Perrigo Company PLC
NYSE:PRGO
Average P/E: 22.1
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.9
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.8
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.8
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.2
25%
1.2
CH
Novartis AG
SIX:NOVN
19.9
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
0%
N/A
US
Pfizer Inc
NYSE:PFE
20
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

In line with most companies in Ireland
Percentile
36th
Based on 255 companies
36th percentile
7.3
Low
0 — 6
Typical Range
6 — 12.9
High
12.9 —
Distribution Statistics
Ireland
Min 0
30th Percentile 6
Median 10.6
70th Percentile 12.9
Max 338.7

Perrigo Company PLC
Glance View

Perrigo Company PLC, a stalwart in the pharmaceutical and healthcare sectors, has carved a niche by specializing in over-the-counter (OTC) health and wellness products. This Dublin-based company traces its origins back to 1887, in Allegan, Michigan, where it began as a modest packager of home remedies. Over the decades, Perrigo has evolved into a global powerhouse that provides affordable and quality healthcare products, distributing them across various markets around the world. Its strategy hinges on delivering effective OTC solutions and a wide array of consumer self-care products, making it a familiar presence in households seeking reliable alternatives to more expensive brand-name pharmaceuticals. Perrigo's business model is centered on offering value to both consumers and retailers. By producing generic versions of well-known drugs, it captures a significant share of the market driven by cost-conscious customers. This approach also involves collaborating with retail giants to supply their private label OTC medications, a mutually beneficial arrangement that allows retailers to offer lower-cost alternatives under their own brands while maintaining healthy margins. Beyond just OTC medications, Perrigo has expanded its offerings to include nutritional products and topical solutions, further diversifying its portfolio and revenue streams. The company's consistent investment in innovation and keen attention to regulatory compliance underscore its commitment to quality and safety, attributes that resonate well in an industry guided by trust and efficacy.

PRGO Intrinsic Value
43.726 USD
Undervaluation 72%
Intrinsic Value
Price $12.025
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett